Home/Pipeline/Zymfentra™

Zymfentra™

Inflammatory bowel disease

MarketedApproved

Key Facts

Indication

Inflammatory bowel disease

Phase

Marketed

Status

Approved

Company

Celltrion

About Celltrion

Celltrion's mission is to promote patient health by making advanced biologics affordable and accessible globally. It has achieved this by evolving from a contract manufacturer into a vertically integrated powerhouse, becoming the world's leading biosimilar producer with a robust pipeline. Its core strategy leverages massive, FDA/EMA-certified manufacturing capacity, a direct global sales network, and a deep R&D pipeline spanning biosimilars and novel biologics to drive growth and secure long-term market leadership.

View full company profile

Therapeutic Areas

Immunology Oncology Autoimmune Diseases Ophthalmology Respiratory

Other Inflammatory bowel disease Drugs

Drug	Company	Phase	Status
DVI-001	Divamics	Preclinical	Approaching PCC selection
DVI-002	Divamics	Preclinical	Lead optimization
Turq-101	Turquoise Biotechnologies	Preclinical	Active
GS-4875	Gilead	Phase 2	Active
Function-based Consortium for IBD	PharmaBiome	Pre-clinical	Active
Galapagos Collaboration	Scipher Medicine	Discovery/Pre-clinical	Active
IBD Subclassification	Bio-Me	Research	Active
Anti-iRhom2 antibodies	SciRhom	Pre-clinical	Active
IBD Multi-omics Dataset	Ovation.io	Commercial	Active
Noa‑001	Noa Therapeutics	Preclinical	Active
Inflectra	EMS	Phase 3	Active
IW-601	ImmuneWalk Therapeutics	Preclinical	Active